Clinical trial
Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally…
NCT00203866 · University of Chicago, Other · Terminated
Key facts
| NCT number | NCT00203866 |
|---|---|
| Title | Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally Advanced/Metastatic Renal Cell Carcinoma |
| Official title | A Randomized Pilot Phase II Trial of Adjuvant Immunization With G250 Peptide andThree Different Dose Levels of IL-2 Following Surgical Resection of Locally Advanced or Metastatic Renal Cell Carcinoma |
| Lead sponsor | University of Chicago, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Renal Cell Carcinoma |
| Intervention type | Drug |
| Interventions | G250 peptide, IL-2 |
| Enrollment | 40 |
| Start date | Oct 1, 2003 |
| Primary completion | Mar 1, 2007 |
| Completion | Mar 1, 2007 |
| First posted | Sep 20, 2005 |
| Last update posted | Sep 5, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: